Ansun Biopharma is a late-stage clinical development company dedicated to saving the lives of vulnerable patient populations through the creation of first-in-class biologics. Our lead product, DAS181, is a multi-function sialidase fusion protein for host-cellprotection in respiratory virus infection, including parainfluenza, influenza and COVID19,. We are also advancing several additional programs in oncology and autoimmune diseases using our sialidase platform technology.